Key facts
- It has raised $810K; the latest was Later Stage VC in Sep 2024.
- Notable investors include Alkemi Growth Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Datar Cancer Genetics
- ·The full record, as it builds
Funding rounds
No funding rounds for Datar Cancer Genetics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Datar Cancer Genetics
Provider of cell-based and molecular genomic services intended for the domain of oncology. The company has a portfolio of tests with a deep pipeline of applications and services in cancer screening, diagnostics, theranostics and monitoring space and its multi-analyte molecular analysis platform identifies the most efficacious drugs, enabling medical practitioners to use sophisticated treatment strategies beyond the conventional perspective.
- Sector
- Healthcare
- HQ
- Nashik, India
- Founded
- 1992
- Employees
- 280
- Website
- datarpgx.com/
- Ownership
- Privately Held (backing)
Datar Cancer Genetics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Datar Cancer Genetics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Datar Cancer Genetics in its N-PORT filings yet. We sweep new filings monthly.